mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma

BACKGROUND: Systemic therapy has proven only marginal effects in hepatocellular carcinoma (HCC) so far. The aim of this study was to evaluate the effect of targeting fibroblast growth factor receptor (FGFR) on tumour and stromal cells in HCC models. METHODS: Human and murine HCC cells, endothelial c...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Cancer
Autors principals: Scheller, T, Hellerbrand, C, Moser, C, Schmidt, K, Kroemer, A, Brunner, S M, Schlitt, H J, Geissler, E K, Lang, S A
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2015
Matèries:
Translational Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4453944/
https://ncbi.nlm.nih.gov/pubmed/25688743
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2014.638
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars